Dermatomyositis etiopathogenesis: a rebel soldier in the muscle
- PMID: 30148802
- PMCID: PMC11669106
- DOI: 10.1097/BOR.0000000000000540
Dermatomyositis etiopathogenesis: a rebel soldier in the muscle
Abstract
Purpose of review: The purpose of this article is to review the etiopathogenesis of dermatomyositis, including the predisposing factors, triggers, inflammatory cells, pathways and target antigens associated with dermatomyositis.
Recent findings: During the last few years, we have made considerable progress in unveiling the etiopathogenesis of dermatomyositis. In the first place, we have defined genes within the major histocompatibility complex locus as the greatest genetic risk factor for the disease. Second, we have demonstrated that certain environmental factors, as well as tumors, may trigger certain dermatomyositis subtypes. Moreover, we have established the importance of the interferon pathway in dermatomyositis pathogenesis compared with other myositis subtypes. But probably, the most remarkable advance has been the discovery of multiple autoantibodies that define groups of patients with characteristic clinical features, prognosis and response to treatment.
Summary: Dermatomyositis cause and pathogenesis have proven to be a complex and fascinating task for the scientific community and the last decade has been full of new findings on how the disease starts and how it causes damage to different organ systems. However, we have still more questions than answers in this topic, answers that will be critical to understanding autoimmunity and finding effective therapies to dermatomyositis.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Similar articles
-
Autoantibodies in polymyositis and dermatomyositis.Curr Rheumatol Rep. 2013 Jun;15(6):335. doi: 10.1007/s11926-013-0335-1. Curr Rheumatol Rep. 2013. PMID: 23591825 Review.
-
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.Front Immunol. 2018 Dec 18;9:2951. doi: 10.3389/fimmu.2018.02951. eCollection 2018. Front Immunol. 2018. PMID: 30619311 Free PMC article. Review.
-
Dermatomyositis: Clinical features and pathogenesis.J Am Acad Dermatol. 2020 Feb;82(2):267-281. doi: 10.1016/j.jaad.2019.06.1309. Epub 2019 Jul 4. J Am Acad Dermatol. 2020. PMID: 31279808 Review.
-
[New autoantibodies in dermatomyositis].Actas Dermosifiliogr. 2009 Apr;100(3):182-9. doi: 10.1016/s0001-7310(09)70533-2. Actas Dermosifiliogr. 2009. PMID: 19457303 Spanish.
-
Immunopathogenesis of juvenile dermatomyositis.Muscle Nerve. 2010 May;41(5):581-92. doi: 10.1002/mus.21669. Muscle Nerve. 2010. PMID: 20405498 Review.
Cited by
-
CAR-T cell therapy in rheumatic diseases: a review article.Clin Rheumatol. 2025 Apr 26. doi: 10.1007/s10067-025-07451-7. Online ahead of print. Clin Rheumatol. 2025. PMID: 40285991 Review.
-
Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis.Int J Ophthalmol. 2020 Sep 18;13(9):1443-1450. doi: 10.18240/ijo.2020.09.17. eCollection 2020. Int J Ophthalmol. 2020. PMID: 32953585 Free PMC article.
-
Recent Updates on the Pathogenesis of Inflammatory Myopathies.Curr Rheumatol Rep. 2024 Dec;26(12):421-430. doi: 10.1007/s11926-024-01164-7. Epub 2024 Sep 24. Curr Rheumatol Rep. 2024. PMID: 39316320 Free PMC article. Review.
-
Interferon type I signature associated with skin disease in juvenile dermatomyositis.Front Med (Lausanne). 2024 Feb 14;11:1214920. doi: 10.3389/fmed.2024.1214920. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38420360 Free PMC article.
-
A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.Expert Rev Clin Immunol. 2024 Feb;20(2):197-209. doi: 10.1080/1744666X.2023.2270737. Epub 2024 Jan 21. Expert Rev Clin Immunol. 2024. PMID: 37842905 Free PMC article. Review.
References
-
- Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134–153. - PubMed
-
- Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28:796–803. - PubMed
-
- Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, et al. Usefulness of antip155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64:523–532. - PubMed
-
Highest level of evidence supporting the association between anti-TIFg and cancer.
-
- Tarricone E, Ghirardello A, Rampudda M, et al. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 2012; 384:128–134. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials